Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
Sandra Ferreira, Emma Guttman‐Yassky, Tiago Torres
Topics & Concepts
Atopic dermatitisMedicineTolerabilityJanus kinasePsoriasisDupilumabPharmacologyDermatologyImmunologyAdverse effectCytokineDermatology and Skin DiseasesAllergic Rhinitis and SensitizationIL-33, ST2, and ILC Pathways